Dr. Jarrard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-263-4757Fax+1 608-265-8852
Education & Training
Johns Hopkins UniversityFellowship, Minimally Invasive Urologic Surgery, 1994 - 1996
University of ChicagoResidency, Urology, 1990 - 1994
University of ChicagoInternship, Transitional Year, 1989 - 1990
University of Virginia School of MedicineClass of 1989
Certifications & Licensure
IL State Medical License 1989 - 2026
WI State Medical License 1996 - 2025
MD State Medical License 1994 - 1996- American Board of Urology Urology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate Start of enrollment: 2000 Feb 01
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
- Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer Start of enrollment: 2011 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 148 citationsResveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteinsMoammir H. Aziz, Minakshi Nihal, Vivian X. Fu, David F. Jarrard, Nihal Ahmad
Molecular Cancer Therapeutics. 2006-05-01 - 1823 citationsChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher Sweeney, Yu-Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard
The New England Journal of Medicine. 2015-08-19 - 605 citationsChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos Kyriakopoulos, Yu-Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard
Journal of Clinical Oncology. 2018-01-31
Journal Articles
- The Impact of Statins in Combination with Androgen Deprivation Therapyin Patients with Advanced Prostate Cancer: A Large Observational StudyNatasza Posielski, Tariq A Khemees, David F Jarrard, Kyle A Richards, Urologic Oncology
Authored Content
- SUO 2020: Drug Intervention for Active Surveillance with ApalutamideDecember 2020
- The Impact of Statins in Combination with Androgen Deprivation Therapyin Patients with Advanced Prostate Cancer: A Large Observational StudyDecember 2018
Press Mentions
Quick Restart of US Hospitals Challenged by Patient Fears: National SurveyMay 5th, 2020
AUA 2019: Second Opinion Cases (Ask the Guidelines!): Castration Resistant Prostate CancerMay 4th, 2019
Study Provides Cellular Explanation for Higher Risk of Prostate Cancer in Aging MenAugust 24th, 2017- Join now to see all
Grant Support
- Modulation Of IGF-II Imprinting In The Aging ProstateNational Cancer Institute2002–2012
- Modulation Of IGF-II Imprinting In The Aging ProstateNational Cancer Institute2008
- Mechanisms For Acquired Changes In Prostate Growth RegulationNational Institute Of Diabetes And Digestive And Kidney Diseases2007
- Modulation Of Genomic Imprinting By Oxidative StressNational Institute Of Diabetes And Digestive And Kidney Diseases2003
- Genetic Events In Human Prostate Cell TransformationNational Cancer Institute1998–2002
Professional Memberships
- Member
- Member
- Society for Urological OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
